| Not Yet Recruiting | Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Pat NCT07485764 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Not Yet Recruiting | A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients Wit NCT07432854 | Dermavon Holdings Limited | Phase 2 / Phase 3 |
| Recruiting | A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With NCT06888193 | UCB Biopharma SRL | Phase 1 |
| Recruiting | A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Ps NCT07234591 | Usynova Pharmaceuticals Ltd. | N/A |
| Not Yet Recruiting | A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis NCT06844799 | Hansoh BioMedical R&D Company | Phase 3 |
| Not Yet Recruiting | A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis NCT06943950 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis NCT06875934 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 |
| Recruiting | Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis NCT06696417 | First Hospital of China Medical University | — |
| Not Yet Recruiting | Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis NCT06779097 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 4 |
| Recruiting | Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Ps NCT06258668 | Bristol-Myers Squibb | — |
| Recruiting | A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderat NCT06506916 | UCB Biopharma SRL | Phase 3 |
| Completed | A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Hea NCT07051538 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents NCT06425549 | UCB Biopharma SRL | Phase 3 |
| Completed | Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque NCT06109818 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Active Not Recruiting | Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis NCT06142357 | Novartis Pharmaceuticals | — |
| Completed | A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Diffe NCT06182384 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Completed | Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis NCT05342428 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 1 |
| Completed | 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treat NCT05155098 | Novartis Pharmaceuticals | — |
| Unknown | Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis NCT05258331 | GC Cell Corporation | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to NCT05020249 | UCB Biopharma SRL | Phase 3 |
| Completed | Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis NCT04999839 | Takeda | Phase 2 |
| Completed | A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaqu NCT04967508 | Samsung Bioepis Co., Ltd. | Phase 3 |
| Unknown | Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis NCT04839016 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study P NCT04718896 | UCB Biopharma SRL | Phase 2 |
| Completed | To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis NCT04566666 | Sun Pharmaceutical Industries Limited | Phase 2 |
| Completed | A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis NCT04612699 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Withdrawn | A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis NCT04614298 | Kyowa Kirin Co., Ltd. | Phase 4 |
| Completed | A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Settin NCT05787236 | Novartis Pharmaceuticals | — |
| Unknown | Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects NCT04367441 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 |
| Unknown | A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque NCT03710681 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic P NCT03412747 | UCB Biopharma SRL | Phase 3 |
| Completed | An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safe NCT03390101 | Biocad | Phase 3 |
| Withdrawn | Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients NCT03146247 | Diamant Thaci | Phase 4 |
| Completed | A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea NCT02982005 | Kyowa Kirin Korea Co., Ltd. | Phase 3 |
| Completed | A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Pa NCT02713295 | AbbVie | — |
| Completed | MSB11022 in Moderate to Severe Chronic Plaque Psoriasis NCT02660580 | Fresenius Kabi SwissBioSim GmbH | Phase 3 |
| Completed | Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis NCT02607774 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Phase 2 Clinical Study of KHK4827 NCT01748539 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Terminated | P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis NCT01708603 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis NCT01622348 | Idera Pharmaceuticals, Inc. | Phase 2 |
| Completed | An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderat NCT01644396 | AbbVie (prior sponsor, Abbott) | Phase 4 |
| Completed | Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities NCT01401452 | AbbVie (prior sponsor, Abbott) | — |
| Completed | An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psori NCT01555606 | Janssen Biotech, Inc. | — |
| Withdrawn | Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Sub NCT01260844 | Abbott | Phase 1 |
| Completed | Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate t NCT01202565 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Seve NCT00710580 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Open Label Continuation Study in Moderate to Severe Psoriasis NCT00626002 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Documentation of Humira in Psoriasis Patients in Routine Clinical Practice NCT01077232 | AbbVie (prior sponsor, Abbott) | — |